ATE205392T1 - Verfahren zur senkung des intraokulären druckes im auge von säugetieren durch verabreichung von gamma-aminobuttersäure-agonisten - Google Patents

Verfahren zur senkung des intraokulären druckes im auge von säugetieren durch verabreichung von gamma-aminobuttersäure-agonisten

Info

Publication number
ATE205392T1
ATE205392T1 AT93907540T AT93907540T ATE205392T1 AT E205392 T1 ATE205392 T1 AT E205392T1 AT 93907540 T AT93907540 T AT 93907540T AT 93907540 T AT93907540 T AT 93907540T AT E205392 T1 ATE205392 T1 AT E205392T1
Authority
AT
Austria
Prior art keywords
chloro
aminobutyric acid
pharmaceutically acceptable
acceptable salt
gamma
Prior art date
Application number
AT93907540T
Other languages
English (en)
Inventor
Mussie Elizabeth Wolde
Guadalupe Ruiz
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE205392T1 publication Critical patent/ATE205392T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT93907540T 1992-03-19 1993-03-16 Verfahren zur senkung des intraokulären druckes im auge von säugetieren durch verabreichung von gamma-aminobuttersäure-agonisten ATE205392T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/856,012 US6077839A (en) 1992-03-19 1992-03-19 Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (GABA) agonists
PCT/US1993/002402 WO1993018762A2 (en) 1992-03-19 1993-03-16 Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (gaba) agonists

Publications (1)

Publication Number Publication Date
ATE205392T1 true ATE205392T1 (de) 2001-09-15

Family

ID=25322685

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93907540T ATE205392T1 (de) 1992-03-19 1993-03-16 Verfahren zur senkung des intraokulären druckes im auge von säugetieren durch verabreichung von gamma-aminobuttersäure-agonisten

Country Status (9)

Country Link
US (1) US6077839A (de)
EP (1) EP0630240B1 (de)
JP (1) JPH07505156A (de)
AT (1) ATE205392T1 (de)
AU (1) AU3810893A (de)
CA (1) CA2132102A1 (de)
DE (1) DE69330749T2 (de)
ES (1) ES2162815T3 (de)
WO (1) WO1993018762A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19525598C2 (de) * 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
AU736514B2 (en) * 1995-07-13 2001-07-26 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Non-allosteric gabaa agonists for treating sleep disorders
EP1220658A1 (de) * 1999-09-28 2002-07-10 H. Lundbeck A/S Schmelzgranulierte zusammensetzung und aus dieser hergestellte darreichungsform mit modifizierter freisetzung
MXPA03007199A (es) * 2001-02-13 2005-02-14 Mann Gerhard Chem Pharm Fab Moduladores del receptor gaba para el tratamiento de enfermedades neurodegenerativas del ojo.
US20040242457A1 (en) * 2003-05-27 2004-12-02 Ashby Charles R. Use of anti-glaucoma drugs to treat visual defects associated with the use of a GABAergic agent
US9623000B2 (en) 2008-07-31 2017-04-18 Dekel Pharmaceuticals Ltd Compositions and methods for treating inflammatory disorders
WO2011113904A1 (en) * 2010-03-17 2011-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
US8784835B2 (en) * 2012-07-02 2014-07-22 Trent Austin Method for producing muscimol and/or reducing ibotenic acid from amanita tissue

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3467756A (en) * 1967-03-16 1969-09-16 Merck & Co Inc Composition and method for treating glaucoma
US3644643A (en) * 1969-10-13 1972-02-22 Unimed Inc Method of reducing intraocular pressure using glycine
US4363818A (en) * 1975-06-04 1982-12-14 Gottlieb Sheldon K Method for relief of burning, itching, and pain of cutaneous and mucosal surfaces
US4171377A (en) * 1978-08-11 1979-10-16 Burton, Parsons & Co., Inc. Ophthalmic solution of tranexamic acid
US4197301A (en) * 1978-10-16 1980-04-08 Allergan Pharmaceuticals, Inc. Topical ophthalmic use of Prazosin
US4322440A (en) * 1980-06-25 1982-03-30 New York University Anticonvulsive compositions and method of treating convulsive disorders
US4565821A (en) * 1983-03-21 1986-01-21 The Texas A&M University System Method and ophthalmic composition for treating ocular hypertension and glaucoma with butyrophenones
US4837021A (en) * 1986-12-31 1989-06-06 Laboratoires P.O.S. Two part tissue irrigating solution
US5066664A (en) * 1990-02-28 1991-11-19 Allergan, Inc. 2-(hydroxy-2-alkylphenylamino)-oxazolines and thiazolines as anti-glaucoma and vasoconstrictive agents
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents

Also Published As

Publication number Publication date
JPH07505156A (ja) 1995-06-08
CA2132102A1 (en) 1993-09-30
EP0630240A1 (de) 1994-12-28
WO1993018762A3 (en) 1993-10-28
AU3810893A (en) 1993-10-21
EP0630240B1 (de) 2001-09-12
DE69330749D1 (de) 2001-10-18
ES2162815T3 (es) 2002-01-16
US6077839A (en) 2000-06-20
DE69330749T2 (de) 2002-07-04
WO1993018762A2 (en) 1993-09-30

Similar Documents

Publication Publication Date Title
ATE195117T1 (de) 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren
NO964939L (no) Fremgangsmåte for fremstilling av virkestoffpreparater i form av en fast lösning av virkestoffet i en polymermatriks, samt virkestoffpreparater fremstilt ved hjelp av denne fremgangsmåte
DE69723869D1 (de) Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten
DE69624234D1 (de) Verfahren zur senkung des intrakulären druckes im auge von säugern unter anwendung von kaliumkanalblokker
ATE205392T1 (de) Verfahren zur senkung des intraokulären druckes im auge von säugetieren durch verabreichung von gamma-aminobuttersäure-agonisten
HUP0001062A2 (hu) NAALADáz gátló hatású foszfinsavszármazékokat tartalmazó gyógyászati készítmények
ES2136723T3 (es) Utilizacion de n-aril-metilen-etilen-diamino-triacetatos, n-aril-metilen-imino-diacetatos o n,n'-diaril-metilen-etilen-diamino-acetatos contra el estres oxidante.
WO2002009702A8 (en) Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
DE69329381D1 (de) Anti-ischaemisches arzneimittel
CA2680324A1 (en) Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
ATE192041T1 (de) Arzneimittel zur prophylaxe und behandlung von katarakt
WO1995034302A3 (en) Method for reducing intraocular pressure in the mammalian eye by administration of calcium chelators
US5190962A (en) Treating hypertension
MX9805317A (es) Agente para la profilaxis y el tratamiento de complicaciones diabeticas.
D'ANDREA et al. Dual mechanism for cAMP-dependent modulation of Ca2+ signalling in articular chondrocytes
JP2001505217A (ja) チエニルシクロヘキシルアミン誘導体の新規な治療用途
ATE200277T1 (de) Substituierte phenylamidine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
RU2003331C1 (ru) Средство дл регулировани сокращени глазного зрачка
KR900009696A (ko) 신규 화합물
DK381983A (da) Fremgangsmaade til fremstilling af spiro(2h-1,4-benzodioxepin-3(5h)4'-piperidin- og -3'-pyrrolidinforbindelser
AU710525B2 (en) Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (GABA) agonists
CA2219280A1 (en) Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties